Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fukushima
Clinical trial register · Japan

Clinical Trials in Fukushima, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca19 GlaxoSmithKline9 Janssen Research & Development, LLC7 AbbVie6 Ono Pharmaceutical Co., Ltd.6
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Fukushima

115 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
120
Yokohama, Suita, Hachiōji, Fukushima
2026-10-30
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
GlaxoSmithKline
Phase 3
610
Fukuoka, Fukushima, Hokkaido, Miyagi, Numakunai, Osaka, Saitama, Tokyo
2026-09-24
Recruiting
4D Molecular Therapeutics
Phase 3
514
Mito, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagoshima, Kita-Gun, Kobe
2026-09-18
Recruiting
AstraZeneca
Phase 3
950
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku
2026-09-16
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Aomori, Chikushino-shi, Chūōku, Fukui-shi, Fukushima, Higashiibaraki-gun, Higashiohmi-shi, Iwakuni-shi
2026-08-24
Active, closed
GlaxoSmithKline
Phase 3
102
Aichi, Chiba, Fukui, Fukuoka, Fukushima, Hokkaido, Kanagawa, Kyoto
2026-06-29
Recruiting
Takeda
Phase 3
300
Nagoya, Fukushima, Gifu, Fukuyama-shi, Amagasaki-shi, Mibu, Bunkyo-ku, Shinagawa-ku
2026-05-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Kitakyushu, Fukushima, Yamagata
2026-05-04
Recruiting
GlaxoSmithKline
Phase 2
200
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Ishikawa, Numakunai
2026-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Kitakyushu, Fukushima
2026-03-18
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Nagoya, Chiba, Kitakyushu-shi, Fukushima, Asahikawa-shi, Sapporo, Kobe, Kanazawa
2026-03-10
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Aichi, Bunkyō City, Chiba, Chūō, Fuchū, Fukuoka, Fukushima, Isehara
2026-03-05
Recruiting
Eli Lilly and Company
Phase 2
450
Chikugo, Fukushima, Hachinohe, Hiratsuka, Karatsu, Kodaira, Kumamoto, Kurume
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Arakawa City, Chikugo, Chiyoda City, Fukuoka, Fukushima, Ginowan, Hiratsuka, Karatsu
2026-02-09
Recruiting
Tokyo Women's Medical University
Phase 3
950
Akita, Chiba, Fukuoka, Fukushima, Fukuyama, Hamamatsu, Hirakata, Hiroshima
2026-01-28
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
Eli Lilly and Company
Phase 2
400
Chikugo, Chiyoda City, Fukushima, Iruma, Karatsu, Kōtō City, Kumamoto, Kure
2025-11-24
Recruiting
BioNTech SE
Phase 3
558
Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku
2025-10-30
Recruiting
Daiichi Sankyo
Phase 3
710
Akashi-shi, Fukuoka, Fukushima, Hidaka-shi, Kōtoku, Kurume-shi, Niigata, Okayama
2025-09-30
Recruiting
BeOne Medicines
Phase 3
500
Nagoya, Nakamuraku, Matsuyama, Fukushima, Hiroshima, Sapporo, Nankoku, Kumamoto
2025-09-04
Recruiting
4D Molecular Therapeutics
Phase 3
480
Nagoya, Hyōgo, Fukushima, Mito, Miyazaki, Ginowan, Chiba, Fukuoka
2025-07-22
Recruiting
Takeda
Phase 3
347
Kasugai-Shi, Nagoya, Toyoake-shi, Chiba, Fukuoka, Fukushima, Hiroshima, Sapporo
2025-07-15
Active, closed
Astellas Pharma Inc
Phase 4
17
Nagoya, Fukushima, Kita-gun, Yokohama, Kyoto, Nagasaki, Ginowan-shi, Hirakata-shi
2025-07-08
Recruiting
AstraZeneca
Phase 2
987
Chiba, Fukuoka, Fukushima, Ginowan-shi, Hachioji-shi, Hamamatsu, Hiroshima, Izumi-shi
2025-06-27
Recruiting
GlaxoSmithKline
Phase 3
981
Kitakyushu-shi, Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki
2025-06-20
Active, closed
Arrowhead Pharmaceuticals
Phase 3
70
Kanazawa, Suita, Fukushima, Okayama, Saitama, Tokyo
2025-06-17
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Chūōku, Fukushima, Hamamatsu, Ichikawa-shi, Kanazawa, Kishiwada-shi, Kita-gun, Komatsu-shi
2025-06-10
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bunkyō City, Fukuoka, Fukushima, Gifu, Kanazawa, Kobe, Kumamoto, Maebashi
2025-06-04
Recruiting
Swedish Orphan Biovitrum
Phase 2
156
Fukushima, Nagasaki, Yokohama
2025-05-28
Recruiting
Biogen
Phase 3
454
Toyoake-shi, Hirosaki-shi, Chiba, Urayasu-Shi, Sapporo, Kitakyushu-shi, Fukushima, Kawasaki-shi
2025-05-08
By invitation
Novo Nordisk A/S
Observational
30
Chiba, Fukui, Fukushima, Hyōgo, Kanagawa, Kawagoe, Miyagi, Nagano
2025-05-02
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Aichi, Chiba, Fukushima, Gunma, Hiroshima, Hyōgo, Ibaraki, Kagawa
2025-04-24
Recruiting
Hoffmann-La Roche
Phase 3
450
Aichi, Chiba, Fukushima, Hiroshima, Hokkaido, Kanagawa, Okayama, Saitama
2025-04-09
Recruiting
Daiichi Sankyo
Phase 3
582
Akashi, Chūōku, Fukushima, Hidaka-Shi, Kōtoku, Kurume-shi, Nagoya, Niigata
2025-03-19
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Kashiwa, Sapporo, Kobe, Yokohama, Chiba, Fukuoka, Fukushima, Ishikawa
2025-02-27
Active, closed
GlaxoSmithKline
Phase 2
307
Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima, Hokkaido, Hyōgo
2025-02-10
Active, closed
AbbVie
Phase 2
150
Hirosaki, Fukushima, Tsukuba, Kanazawa
2025-01-20
Active, closed
Ipsen
Phase 3
18
Chiba, Fukushima, Hiroshima, Hokkaido, Kagawa, Kagoshima, Nagano, Nagasaki
2025-01-16
Active, closed
argenx
Phase 3
631
Nagoya, Fukushima, Hiroshima, Sapporo, Nishinomiya-shi, Tsukuba, Kahoku-gun, Kanazawa
2025-01-15
Recruiting
GlaxoSmithKline
Phase 3
520
Shibuya-Ku, Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki
2024-12-16
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
23
Nagoya, Sapporo, Kobe, Osaka, Chuo-ku, Chiba, Fukuoka, Fukushima
2024-11-25
By invitation
Sanofi
Phase 2
900
Sakaidechō, Chūō, Ube, Fukushima, Kyoto, Miyazaki
2024-09-30
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Isesaki-shi, Kagoshima, Kyoto
2024-08-13
Active, closed
Genmab
Phase 3
379
Toyoake, Matsuyama, Fukuoka, Fukushima, Sapporo, Amagasaki, Kagoshima, Isehara
2024-08-13
Recruiting
ARCAGY/ GINECO GROUP
Phase 3
250
Bunkyō City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume
2024-07-30
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Sapporo, Kanazawa, Shōwaku, Chūōku, Yufu-Shi, Chuo-ku, Tokyo, Fukushima, Higashi
2024-07-09
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
20
Nagoya, Akita, Urayasu-shi, Fukuoka, Kitakyushu-shi, Kurume-shi, Fukushima, Gifu
2024-05-17
Recruiting
Boehringer Ingelheim
Phase 2
175
Akita, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagawa, Kita-gun, Kagoshima, Kashihara
2024-05-15
Active, closed
AbbVie
Phase 2
156
Gamagori-shi, Nagakute, Kashiwa-shi, Urayasu-shi, Kitakyushu-shi, Fukushima, Gifu, Ogaki-shi
2024-03-23
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Kashiwa, Sapporo, Kobe, Yokohama, Chuo Ku, Fukuoka, Fukushima, Ishikawa
2024-03-12
Active, closed
AbbVie
Observational
1,200
Nagoya, Toyoake, Hirosaki, Chiba, Sakura, Fukuoka, Fukushima, Asahikawa-shi
2024-02-19
Recruiting
Yonsei University
Phase 2
198
Kurume, Fukushima, Tsu, Sendai, Niigata, Hidaka, Tokushima, Tokyo
2024-01-22
Recruiting
AstraZeneca
Phase 3
625
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,902
Akashi-shi, Akita, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu
2023-11-14
Active, closed
AstraZeneca
Phase 3
5,511
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun
2023-10-05
Active, closed
Gilead Sciences
Phase 3
654
Aichi, Aoba-ku, Bunkyō City, Chiba, Chūōku, Ehime, Fukushima, Kagoshima
2023-05-08
Recruiting
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Fukushima
2023-02-28
Active, closed
Genmab
Phase 3
900
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe, Tsukuba
2023-02-08
Active, closed
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562Diffuse Large B-Cell Lymphoma
Tanabe Pharma Corporation
Phase 1/2
46
Nagoya, Kashiwa-shi, Fukuoka, Iizuka-shi, Fukushima, Gifu, Ota-shi, Sapporo
2023-01-30
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsErythromycin·Rina-S·Itraconazole·Bevacizumab
Genmab
Phase 1/2
952
Fukushima, Ōta, Sapporo, Akashi, Hidaka, Nagaizumi-chō, Koto, Shinjuku-ku
2022-12-07
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Aichi, Akita, Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima
2022-12-05
Active, closed
AstraZeneca
Phase 3
1,174
Akashi-shi, Chiba, Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kashiwa
2022-11-28
Active, closed
Sanofi
Phase 2
187
Nagaoka, Hamamatsu, Chūō, Fukushima, Osaka, Ōita, Saitama
2022-11-25
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Chiba, Fukushima, Higashimatsuyama-shi, Isehara-shi, Itabashi-ku, Kawasaki-shi, Morioka, Nagasaki
2022-11-21
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
100
Ehime, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima, Kanagawa
2022-11-04
Active, closed
Eli Lilly and Company
Phase 3
8,000
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Fukuyama, Gifu, Hachioji-shi
2022-10-04
Active, closed
Genmab
Phase 3
549
Nagoya, Toyoake, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe
2022-09-20
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Bunkyō City, Chūōku, Fujiidera-shi, Fukuoka, Fukushima, Hachinohe, Hachiōji, Hamamatsu
2022-09-13
Active, closed
Hoffmann-La Roche
Phase 3
139
Chiba, Fukuoka, Fukushima, Hyōgo, Kanagawa, Miyagi, Osaka, Tokyo
2022-08-30
Active, closed
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
NCT05814159Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
DrugAnakinra
Swedish Orphan Biovitrum
Phase 3
15
Fukushima, Kobe, Yokohama, Matsumoto, Bunkyō-Ku, Shinjuku-Ku, Gifu
2022-08-24
Active, closed
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
NCT06696716Pemphigus, Steroid-resistant Pemphigus
DrugTirabrutinib
Ono Pharmaceutical Co., Ltd.
Phase 3
34
Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hokkaido, Kagoshima, Kanagawa
2022-08-15
Active, closed
Gilead Sciences
Phase 3
443
Aichi, Aoba-ku, Bunkyō City, Chūōku, Ehime, Fukushima, Inamachi, Kagoshima
2022-07-25
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
15
Aichi, Fukuoka, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2022-07-12
Active, closed
Janssen Research & Development, LLC
Phase 2
36
Fukuoka, Fukushima, Kanagawa, Kawachi-Nagano, Matsudo-shi, Matsumoto, Sendai, Tokyo
2022-07-05
Recruiting
AstraZeneca
Observational
300
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2022-06-02
Active, closed
AstraZeneca
Phase 3
644
Chūōku, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun, Kōtoku
2022-05-16
Active, closed
ARCAGY/ GINECO GROUP
Phase 3
260
Fukuoka, Fukushima, Kōtoku, Saitama
2022-04-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Kamogawa, Kashiwa-Shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Tsukuba, Kanazawa
2022-03-07
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Kashiwa-shi, Yoshida-gun, Fukushima, Isehara-shi, Nagasaki, Bunkyo-ku, Bunkyō City, Fukuoka
2022-02-28
Active, closed
GlaxoSmithKline
Phase 3
21
Nagoya, Kamogawa, Kashiwa, Matsuyama, Fukushima, Maebashi, Shibukawa, Numakunai
2022-02-10
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Nagoya, Fukushima, Kobe, Nishinomiya-shi, Kagoshima, Kyoto, Miyazaki, Ōtsu
2022-01-13
Active, closed
AstraZeneca
Observational
1,620
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2021-12-21
Active, closed
Amgen
Phase 3
303
Nagoya, Akita, Kamogawa-shi, Yoshida-gun, Fukuoka, Kurume-shi, Fukushima, Maebashi
2021-11-02
Active, closed
AstraZeneca
Phase 3
732
Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun
2021-10-18
Active, closed
Beeline Medicines Corporation
Phase 2
248
Chiba, Eiheiji-cho,Yoshida-gun, Kitakyushu, Fukushima, Sapporo, Kanazawa, Sendai, Bunkyo-ku
2021-10-11
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Isehara-Shi, Kumamoto-Shi Chuo-Ku, Naha, Osaka-Shi Chuo-Ku, Shinden, Koto-Ku, Fukushima, Hiroshima
2021-08-27
Recruiting
Zimmer Biomet Shoulder Arthroplasty PMCF
NCT04984291Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity
Zimmer Biomet
Not applicable
584
Fukui, Fukushima, Okinawa, Tokyo
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Nagoya, Isehara, Suwa, Suita, Shinjuku Ku, Fukushima, Ishikawa, Kyoto
2021-07-27
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Fukuoka, Fukushima, Kanazawa, Kashiwa, Kobe, Maebashi, Nagoya, Sapporo
2021-05-19
Active, closed
AstraZeneca
Phase 3
1,157
Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima
2021-04-26
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Bunkyo-ku, Tokyo, Fukui-shi, Fukui, Fukushima, Gifu, Hamamatsu-shi, Shizuoka, Hatsukaichi-shi, Hiroshima, Hiroshima-shi, Hiroshima, Izunokuni-shi, Shizuoka
2021-04-01
Active, closed
Genmab
Phase 3
483
Fukuoka, Fukushima, Fukuyama, Hokkaido, Kashiwa, Kyoto, Matsuyama, Mie
2021-01-13
Active, closed
Amgen
Phase 1/2
181
Akita, Kashiwa-shi, Fukushima, Yokohama, Yokohami-shi
2021-01-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Nagoya, Toon-shi, Fukushima, Akashi, Nishinomiya-Shi, Sagamihara, Sendai, Nagasaki
2020-12-02
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Fukushima, Kanazawa, Kashiwa-shi, Kita-ku, Kumamoto, Matsumoto-shi, Nagoya, Shibuya-ku
2020-11-03
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 1
59
Bunkyō City, Fukushima, Iruma, Kyoto, Nagasaki, Osaka, Sakai, Shinagawa-Ku
2020-10-30
Active, closed
GlaxoSmithKline
Phase 3
302
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Numakunai, Okayama
2020-10-01
Active, closed
AbbVie
Phase 3
531
Nagoya, Yoshida-gun, Fukuoka, Fukushima, Fukuyama, Sapporo, Kobe, Higashiibaraki-gun
2020-09-10
Active, closed
AbbVie
Phase 3
330
Nagoya, Toyoake, Aomori, Chiba, Kashiwa-shi, Toon-shi, Fukuoka, Fukushima
2020-08-31
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
Fukushima, Nagoya, Shibuya-ku
2020-08-25
Active, closed
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
DrugsRituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab·Lenvatinib
Genmab
Phase 1/2
78
Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto
2020-08-20
Active, closed
AstraZeneca
Phase 3
818
Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku
2020-04-16
Active, closed
GlaxoSmithKline
Phase 3
325
Shibuya-Ku, Aichi, Chiba, Ehime, Fukushima, Gifu, Gunma, Hokkaido
2020-04-02
Active, closed
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
RECORDATI GROUP
Observational
429
Fukushima, Himeji-shi
2019-12-12
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bunkyō City, Chiba, Chikushino-shi, Ehime, Fujiidera-shi, Fukuoka, Fukuoka-ken, Fukushima
2019-09-26
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Fukushima, Iruma-gun, Kanagawa, Kitakyusyu-Shi, Kofu, Ōgaki, Sapporo, Sendai
2019-08-15
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Vincristine
Takeda
Phase 3
245
Chiba, Kashiwa, Fukushima, Sapporo, Isehara, Okayama
2018-10-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Nagoya, Kashiwa, Kitakyushu, Akashi, Kawasaki, Yokohama, Yufu, Fukushima
2018-04-24
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Chūō, Fukuoka, Fukushima, Miyagi, Miyazaki, Tokyo, Tōon, Tsu
2017-06-26
Active, closed
AstraZeneca
Phase 3
987
Chūōku, Fukuoka, Fukushima, Himeji-shi, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi
2017-03-27
Active, closed
AstraZeneca
Phase 3
953
Bunkyō City, Fukushima, Habikino-shi, Hirosaki-shi, Iizuka-shi, Iwakuni-shi, Kanazawa, Kishiwada-shi
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,118
Fukushima, Himeji-shi, Hirakata-shi, Hirosaki-shi, Iizuka-shi, Iwakuni-shi, Izumi-shi, Kanazawa
2015-07-21
Rows per page Showing 1–115 of 115
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/fukushima

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 115 of those studies with a site in Fukushima.

How many clinical trials are recruiting in Fukushima?

50 of the 115 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 63 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fukushima), 115 studies
PhaseStudiesRecruitingShare
Phase 3773267%
Phase 2191016.5%
Phase 1/2635.2%
Observational514.3%
Phase 2/3423.5%
Phase 1211.7%
Not applicable110.9%
Phase 4100.9%

Most active sponsors

Lead sponsors with the most studies (Fukushima)
Lead sponsorStudiesRecruiting
AstraZeneca197
GlaxoSmithKline94
Janssen Research & Development, LLC73
AbbVie60
Genmab61
Ono Pharmaceutical Co., Ltd.63
Eli Lilly and Company54
Novartis Pharmaceuticals53
Alexion Pharmaceuticals, Inc.30
Hoffmann-La Roche31
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.